Accelerator™ Drug Development

Supporting accelerated global CVOT execution through site expertise and operational alignment

Coordinated site strategy and therapeutic area expertise, enabled through the Accelerator™ Drug Development framework, supported more efficient execution of a large-scale global cardiovascular outcomes trial.

Development challenge

Global cardiovascular outcomes trials (CVOTs) require large patient populations, long study durations, and consistent execution across multiple regions. Variability in site activation, differences in regional performance, and delays in patient enrollment can extend timelines and introduce operational risk.

During planning and initiation of a global Phase III CVOT across more than 30 countries and 1,400+ sites, the customer needed to activate sites and initiate enrollment at scale while maintaining aggressive, investor-driven timelines. There was concern that variability in site start-up and regional execution could delay first patient enrollment and disrupt study continuity.

Aligning site strategy with therapeutic and regional expertise

To support execution, global site strategy was aligned early with established investigator networks and therapeutic area expertise in cardiovascular research, enabled through the Accelerator™ Drug Development framework.

Sites were selected and prioritized based on experience in CVOTs and demonstrated enrollment performance. Leveraging existing relationships supported more efficient feasibility assessment and accelerated site activation across regions.

From project initiation, integrated clinical and supply teams coordinated closely to align timelines and ensure site readiness, enabling first site activation ahead of the customer's planned milestone.

Maintaining enrollment consistency across regions

As the study progressed, ongoing coordination across regions supported consistent execution and proactive issue management.

Enrollment performance was actively monitored across sites and geographies, allowing early identification of variability and targeted adjustments. Custom dashboards and structured site activation reviews supported faster decision-making and issue resolution.

This approach enabled first patient enrollment one month ahead of the customer's projected timeline and supported sustained enrollment performance across regions.

At a glance

Program focus
Global Phase III cardiovascular outcomes trial (CVOT) across 30+ countries, 1,400+ sites, and 8,000+ patients

Approach
Alignment of global site strategy with established investigator networks and coordinated clinical and regional execution within the Accelerator™ Drug Development framework

Operational parameters addressed
Site feasibility and selection, site activation timelines, patient enrollment performance, and cross-regional coordination

Key Technical Outcome
Prioritizing experienced CVOT sites and enabling integrated execution across teams supported accelerated site activation and reduced variability in enrollment across geographies

Development impact
First site activation achieved ahead of plan and approximately 85 days faster than industry benchmarks for similar CVOT studies; first patient enrolled one month early; site network expanded by 66% to accelerate enrollment and event rates

Development outcome

Early alignment of site strategy and integrated execution across clinical and supply teams enabled faster study start-up and more predictable enrollment.

First site activation was achieved ahead of plan and approximately 85 days faster than industry benchmarks for similar CVOT studies. With confidence in site activation performance, the customer expanded the number of active sites by 66% to further accelerate enrollment and event rates.

Together, these efforts supported more efficient execution of a complex global CVOT while maintaining operational consistency at scale.